Covariates | Category | Outcome status | ||
Attrition (%) | Censored (%) | Total (%) | ||
Baseline ART regimen | D4T-3TC-NVP | 14 (42.4) | 19 (57.6) | 33 (12.99) |
AZT-3TC-NVP | 56 (37.1) | 95 (62.9) | 151 (59.45) | |
TDF-3TC-EFV | 3 (20) | 12 (80) | 15 (5.91) | |
ABC-3TC-EFV | 2 (28.6) | 5 (71.4) | 7 (2.76) | |
AZT-3TC-EFV | 7 (41.2) | 10 (58.8) | 17 (6.69) | |
ABC-3TC-NVP | 7 (63.6) | 4 (36.4) | 11 (4.33) | |
Others | 3 (15) | 17 (85) | 20 (7.87) | |
Adherence | Good | 45 (23.1) | 150 (76.9) | 195 (76.77) |
Fair | 4 (66.7) | 2 (33.3) | 6 (2.36) | |
Poor | 43 (81.1) | 10 (18.9) | 53 (20.87) | |
CPT | Given | 75 (33.8) | 147 (66.2) | 222 (87.4) |
Not given | 17 (53.1) | 15 (46.9) | 32 (12.6) | |
Drug side effect | Yes | 44 (56.4) | 34 (43.6) | 78 (30.7) |
No | 48 (27.3) | 128 (72.7) | 176 (69.3) | |
Drug substitution | Yes | 22 (29.7) | 52 (70.3) | 74 (29.1) |
No | 70 (38.9) | 110 (61.1) | 180 (70.9) | |
Last outcome | Active/on follow-up | 0 (0) | 127 (100) | 127 (50.0) |
Transfer out | 0 (0) | 35 (100) | 35 (13.8) | |
Attrition/interrupted | 92 (100) | 0 (0) | 92 (36.2) |
ABC, abacavir; ART, antiretroviral treatment; AZT, zidovudine; CPT, cotrimoxazole preventive therapy; D4T, stavudine; EFV, efavirenz; NVP, nevirapine; 3TC, lamivudine; TDF, tenofovir.